The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Solov’eva Yu.A.

Kaluga Regional Oncology Clinical Hospital

Rubtsova N.A.

P.A. Herzen Moscow Oncology Research Institute — Branch of the National Medical Radiology Research Center

Khodzhibekova M.M.

P.A. Herzen Moscow Oncology Research Institute — Branch of the National Medical Radiology Research Center

Kudryavtsev I.Yu.

Kaluga Regional Oncology Clinical Hospital

Mokhov I.V.

Kaluga Regional Oncology Clinical Hospital

Diagnostic value of cross-sectional imaging modalities in assessment of peritoneal carcinomatosis

Authors:

Solov’eva Yu.A., Rubtsova N.A., Khodzhibekova M.M., Kudryavtsev I.Yu., Mokhov I.V.

More about the authors

Journal: P.A. Herzen Journal of Oncology. 2024;13(5): 82‑88

DOI: 10.17116/onkolog20241305182

Read: 1368 times

Download PDF (RU)
Contact the author
Table of contents

DIAGNOSTIC VALUE OF CROSS-SECTIONAL IMAGING MODALITIES IN ASSESSMENT OF PERITONEAL CARCINOMATOSIS
DIAGNOSTIC VALUE OF CROSS-SECTIONAL IMAGING MODALITIES IN ASSESSMENT OF PERITONEAL CARCINOMATOSIS

To cite this article:

Solov’eva YuA, Rubtsova NA, Khodzhibekova MM, Kudryavtsev IYu, Mokhov IV. Diagnostic value of cross-sectional imaging modalities in assessment of peritoneal carcinomatosis. P.A. Herzen Journal of Oncology. 2024;13(5):82‑88. (In Russ.)
https://doi.org/10.17116/onkolog20241305182

Подписка 2026 Онкология. Журнал им. П.А. Герцена (P.A. Herzen Journal of Oncology)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Abstract:

The aim of this article is to provide a modern view on the possibilities of radiological imaging modalities in preoperative assessment of peritoneal carcinomatosis (PC) and disease staging, and its critical role in determining treatment decision in malignant neoplasms (MN) of the abdominal cavity and pelvis. Cross-sectional imaging modalities plays an important role in disease staging of many different types of cancer as well as in detecting, characterizing and quantification of peritoneal deposits. Among imaging modalities, computed tomography (CT) is widely available, fast and commonly used for evaluation of peritoneal metastases. However, depending on primary tumor localization and histology the accurate assessment of distant metastases may require the use of a combination of two or more imaging methods, including magnetic resonance imaging (MRI) and positron emission tomography combined with computed tomography (PET/CT). Each imaging procedure has advantages and disadvantages, and particular imaging techniques are recommended based on patient conditions. The purpose of this review is to report the main role of imaging in the diagnosis of PC, limitations and typical radiological findings in the most common MN accompanied by spread of cancer cells to the peritoneum.

Keywords:

peritoneal carcinomatosis
CT
MRI
18F-FDG PET/CT

Authors:

Solov’eva Yu.A.

Kaluga Regional Oncology Clinical Hospital

Rubtsova N.A.

P.A. Herzen Moscow Oncology Research Institute — Branch of the National Medical Radiology Research Center

Khodzhibekova M.M.

P.A. Herzen Moscow Oncology Research Institute — Branch of the National Medical Radiology Research Center

Kudryavtsev I.Yu.

Kaluga Regional Oncology Clinical Hospital

Mokhov I.V.

Kaluga Regional Oncology Clinical Hospital

Received:

18.08.2024

Accepted:

19.09.2024

Close metadata

References:

  1. Solomennyi SV, Minigazimov RS. Peritoneal carcinomatosis. Review of the World experience. Creative Surgery and Oncology. 2013;(4):115-119. (In Russ.). https://doi.org/10.24060/2076-3093-2013-0-4-115-119
  2. Chia CS, Wong LCK, Hennedige TP, et al. Prospective comparison of the performance of MRI versus CT in the detection and evaluation of peritoneal surface malignancies. Cancers (Basel). 2022;14(13):3179.
  3. Kaprin AD, Starinskii VV, Shakhzadova AO, eds. The state of cancer care for the Russian population in 2023. M.: Moscow State Scientific Research Oncological Institute named after P.A. Herzen — branch of the Federal State Budgetary Institution «Research Institute of Radiology» of the Ministry of Health of the Russian Federation; 2024;262. (In Russ.).
  4. Kaprin AD, Starinskii VV, Shakhzadova AO, Lisichnikova IV, eds. Malignant neoplasms in Russia in 2022 (morbidity and mortality). M.: P.A. Herzen Moscow State Scientific Research Oncological Institute — branch of the Federal State Budgetary Institution «National Research Radiological Center» of the Ministry of Health of the Russian Federation; 2023;275. (In Russ.).
  5. Kotsopoulos J, Rosen B, Fan I, Moody J, McLaughlin JR, Risch H, May T, Sun P, Narod SA. Ten-year survival after epithelial ovarian cancer is not associated with BRCA mutation status. Gynecol Oncol. 2016;140(1):42-47.  https://doi.org/10.1016/j.ygyno.2015.11.009
  6. Sushkov OI, Shelygin YuA, Achkasov SI, Ponomarenko AA, Shubin VP, Saifutdinova KR. Prognostic factors of survival of patients operated for peritoneal carcinomatosis in colon cancer. N.I. Pirogov Journal of Surgery. 2019;(8 Issue 2):16-23. (In Russ.). https://doi.org/10.17116/hirurgia201908216
  7. Sushkov OI, Achkasov SI. Peritoneal carcinomatosis in colon cancer. Treatment approaches (literature review). Coloproctology. 2016;(4):69-79. (In Russ.). https://doi.org/10.33878/2073-7556-2016-0-4-69-79
  8. Koemans WJ, Lurvink RJ, Grootscholten C, Verhoeven RHA, de Hingh IH, van Sandick JW. Synchronous peritoneal metastases of gastric cancer origin: incidence, treatment and survival of a nationwide Dutch cohort. Gastric Cancer. 2021;24(4):800-809.  https://doi.org/10.1007/s10120-021-01160-1
  9. Fiorin de Vasconcellos V, Rcc Bonadio R, Avanço G, Negrão MV, Pimenta Riechelmann R. Inpatient palliative chemotherapy is associated with high mortality and aggressive end-of-life care in patients with advanced solid tumors and poor performance status. BMC Palliat Care. 2019;18(1):42. 
  10. Jacquet P, Sugarbaker PH. Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. Cancer Treat Res. 1996;82:359-374.  https://doi.org/10.1007/978-1-4613-1247-5_23
  11. Sadeghi B, Arvieux C, Glehen O, et al. Peritoneal carcinomatosis from non-gynecologic malignancies: results of the EVOCAPE 1 multicentric prospective study. Cancer. 2000;88(2):358-363. 
  12. Shiozaki H, Elimova E, Slack RS, et al. Prognosis of gastric adenocarcinoma patients with various burdens of peritoneal metastases. J Surg Oncol. 2016;113(1): 29-35.  https://doi.org/10.1002/jso.24087
  13. Gill RS, Al-Adra DP, Nagendran J, Campbell S, Shi X, Haase E, Schiller D. Treatment of gastric cancer with peritoneal carcinomatosis by cytoreductive surgery and HIPEC: a systematic review of survival, mortality, and morbidity. J Surg Oncol. 2011;104(6):692-698.  https://doi.org/10.1002/jso.22017
  14. Sugarbaker PH, Cunliffe WJ, Belliveau J, de Bruijn EA, Graves T, Mullins RE, Schlag P. Rationale for integrating early postoperative intraperitoneal chemotherapy into the surgical treatment of gastrointestinal cancer. Semin Oncol. 1989;16(4 Suppl. 6):83-97.  https://doi.org/10.1007/978-2-8178-0782-9_67
  15. Yonemura Y, Endo Y, Yamaguchi T, Fujimura T, Obata T, Kawamura T, Nojima N, Miyazaki I, Sasaki T. Mechanisms of the formation of the peritoneal dissemination in gastric cancer. Int J Oncol. 1996;8(4):795-802.  https://doi.org/10.3892/ijo.8.4.795
  16. Verwaal VJ, van Ruth S, Witkamp A, Boot H, van Slooten G, Zoetmulder FA. Long-term survival of peritoneal carcinomatosis of colorectal origin. Ann Surg Oncol. 2005;12(1):65-71.  https://doi.org/10.1007/s10434-004-1167-z
  17. Sugarbaker PH. Peritoneum as the first-line of defense in carcinomatosis. J Surg Oncol. 2007;95(2): 93-96.  https://doi.org/10.1002/jso.20676
  18. Gill RS, Al-Adra DP, Nagendran J, Campbell S, Shi X, Haase E, Schiller D. Treatment of gastric cancer with peritoneal carcinomatosis by cytoreductive surgery and HIPEC: a systematic review of survival, mortality, and morbidity. J Surg Oncol. 2011;104(6):692-698.  https://doi.org/10.1002/jso.22017
  19. Maksimov SYa, Sobolev IV, Khadzhimba AS, Il’in AA, Gershfel’d ED, Reies-Sant’yago DK. Cytoreductive operations in oncogynecology. Practical Oncology. 2016;17(3):184-199. (In Russ.). https://doi.org/10.31917/1703184
  20. Petrova IYu, Medvednikov AA, Dvornichenko VV, Radostev SI. Treatment of patients with peritoneal carcinomatosis in ovarian cancer. Quality Management System: Experience and Prospects. 2022;(11):298-300. (In Russ.). https://doi.org/10.17116/onkolog202090615
  21. Eisenkop SM, Friedman RI, Wang HJ. Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: a prospective study. Gynecol Oncol. 1998;69(2):103-108. 
  22. Horowitz NS, Miller A, Rungruang B, Richard SD, Rodriguez N, Bookman MA, Hamilton CA, Krivak TC, Maxwell GL. Does aggressive surgery improve outcomes? Interaction between preoperative disease burden and complex surgery in patients with advanced-stage ovarian cancer: an 129 analysis of GOG 182. J Clin Oncol. 2015;33(8):937-943. 
  23. Jones NL, Chen L, Chatterjee S, Tergas AI, Burke WM, Hou JY, Ananth CV, Neugut AI, Hershman DL, Wright JD. National trends in extended procedures for ovarian cancer debulking surgery. Int J Gynecol Cancer. 2018;28(1):19-25.  https://doi.org/10.1097/igc.0000000000001132
  24. Bagul K, Vijaykumar DK, Rajanbabu A, Antony MA, Ranganathan V. Advanced primary epithelial ovarian and peritoneal carcinoma — does diagnostic accuracy of preoperative CT scan for detection of peritoneal metastatic sites reflect into prediction of suboptimal debulking? A prospective study. Indian J Surg Oncol. 2017;8(2):98-104. 
  25. Van’t Sant I, Engbersen MP, Bhairosing PA, Lambregts DMJ, Beets-Tan RGH, van Driel WJ, Aalbers AGJ, Kok NFM, Lahaye MJ. Diagnostic performance of imaging for the detection of peritoneal metastases: a meta-analysis. Eur Radiol. 2020;30(6):3101-3112. https://doi.org/10.1007/s00330-019-06524-x
  26. Reginelli A, Giacobbe G, Del Canto MT, et al. Peritoneal carcinosis: what the radiologist needs to know. Diagnostics (Basel). 2023;13(11):1974. https://doi.org/10.3390/diagnostics13111974
  27. Dohan A, Hobeika C, Najah H, Pocard M, Rousset P, Eveno C. Preoperative assessment of peritoneal carcinomatosis of colorectal origin. J Visc Surg. 2018;l155(4):293-303.  https://doi.org/10.1016/j.jviscsurg.2018.01.002
  28. Moran BJ. Decision-making and technical factors account for the learning curve in complex surgery. J Public Health (Oxf). 2006;28(4):375-378. 
  29. Kim WH, Won KS, Zeon SK, Ahn BC, Gayed IW. Peritoneal carcinomatosis in patients with ovarian cancer. Enhanced CT versus 18F-FDG PET/CT. Clin Nucl Med. 2013;38(2):93-97.  https://doi.org/10.1097/rlu.0b013e31826390ec
  30. Smeenk RM, Verwaal VJ, Zoermulder FA. Learning curve of combined modality treatment in peritoneal surface disease. Br J Surg. 2007;94(11):1408-1414. https://doi.org/10.1002/bjs.5863
  31. Jacquet P, Sugarbaker PH. Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. Cancer Treat Res. 1996;82:359-374.  https://doi.org/10.1007/978-14613-1247-5_23
  32. Nasser S, Lazaridis A, Evangelou M, Jones B, Nixon K, Kyrgiou M, Gabra H, Rockall A, Fotopoulou C. Correlation of pre-operative CT findings with surgical and histological tumor dissemination patterns at cytoreduction for primary advanced and relapsed epithelial ovarian cancer: a retrospective evaluation. Gynecol Oncol. 2016;143(2):264-269. 
  33. Chandrashekhara SH, Thulkar S, Srivastava DN, Kumar L, Hariprasad R, Kumar S, Sharma MC. Pre-operative evaluation of peritoneal deposits using multidetector computed tomography in ovarian cancer. Br J Radiol. 2011;84(997):38-43.  https://doi.org/10.1259/bjr/87415692
  34. Ferrandina G, Sallustio G, Fagotti A, Vizzielli G, Paglia A, Cucci E, Margariti A, Aquilani L, Garganese G, Scambia G. Role of CT scan-based and clinical evaluation in the preoperative prediction of optimal cytoreduction in advanced ovarian cancer: a prospective trial. Br J Cancer. 2009;101(7):1066-1073. https://doi.org/10.1038/sj.bjc.6605292
  35. Kyriazi S, Kaye SB, de Souza NM. Imaging ovarian cancer and peritoneal metastases — current and emerging techniques. Nat Rev Clin Oncol. 2010;7(7):381-393.  https://doi.org/10.1038/nrclinonc.2010.47
  36. Javadi S, Ganeshan DM, Qayyum A, Iyer RB, Bhosale P. Ovarian cancer, the revised FIGO staging system and the role of imaging. AJR Am J Roentgenol. 2016;206(6):1351-1360. https://doi.org/10.2214/ajr.15.15199
  37. Coakley FV, Choi PH, Gougoutas CA, Pothuri B, Venkatraman E, Chi D, Bergman A, Hricak H. Peritoneal metastases: detection with spiral CT in patients with ovarian cancer. Radiology. 2002;223(2):495-499. 
  38. Tsili AC, Tsampoulas C, Argyropoulou M, Navrozoglou I, Alamanos Y, Paraskevaidis E, Efremidis SC. Comparative evaluation of multidetector CT and MR imaging in the differentiation of adnexal masses. Eur Radiol. 2008;18(5):1049-1057. https://doi.org/10.1007/s00330-007-0842-4
  39. Gu P, Pan LL, Wu SQ, Sun L, Huang G. CA 125, PET alone, PET-CT, CT and MRI in diagnosing recurrent ovarian carcinoma: a systematic review and meta-analysis. Eur J Radiol. 2009;71(1):164-174.  https://doi.org/10.1016/j.ejrad.2008.02.019
  40. Low RN, Barone RM, Lucero J. Comparison of MRI and CT for predicting the Peritoneal Cancer Index (PCI) preoperatively in patients being considered for cytoreductive surgical procedures. Ann Surg Oncol. 2015;22(5):1708-1715. https://doi.org/10.1245/s10434-014-4041-7
  41. Gadelhak B, Tawfik AM, Saleh GA, Batouty NM, Sobh DM, Hamdy O, Refky B. Extended abdominopelvic MRI versus CT at the time of adnexal mass characterization for assessing radiologic peritoneal cancer index (PCI) prior to cytoreductive surgery. Abdom Radiol (NY). 2019;44(6):2254-2261. https://doi.org/10.1007/s00261-019-01939-y
  42. Dresen RC, De Vuysere S, De Keyzer F, Van Cutsem E, Prenen H, Vanslembrouck R, De Hertogh G, Wolthuis A, D’Hoore A, Vandecaveye V. Whole-body diffusion-weighted MRI for operability assessment in patients with colorectal cancer and peritoneal metastases. Cancer Imaging. 2019;19(1):1.  https://doi.org/10.1186/s40644-018-0187-z
  43. Veron Sanchez A, Bennouna I, Coquelet N, Cabo Bolado J, Pinilla Fernandez I, Mullor Delgado LA, Pezzullo M, Liberale G, Gomez Galdon M, Bali MA. Unravelling peritoneal carcinomatosis using cross-sectional imaging modalities. Diagnostics (Basel). 2023;13(13):2253.
  44. Bozkurt M, Doganay S, Kantarci M, Yalcin A, Eren S, Atamanalp SS, Yuce I, Yildirgan MI. Comparison of peritoneal tumor imaging using conventional MR imaging and diffusion-weighted MR imaging with different b values. Eur J Radiol. 2011;80(2):224-228.  https://doi.org/10.1016/j.ejrad.2010.06.004
  45. Fujii S, Matsusue E, Kanasaki Y, Kanamori Y, Nakanishi J, Sugihara S, Kigawa J, Terakawa N, Ogawa T. Detection of peritoneal dissemination in gynecological malignancy: evaluation by diffusion-weighted MR imaging. Eur Radiol. 2008;18(1):18-23.  https://doi.org/10.1007/s00330-007-0732-9
  46. Espada M, Garcia-Flores JR, Jimenez M, Alvarez-Moreno E, De Haro M, Gonzalez-Cortijo L, Hernandez-Cortes G, Martinez-Vega V, Sainz De La Cuesta R. Diffusion-weighted magnetic resonance imaging evaluation of intra-abdominal sites of implants to predict likelihood of suboptimal cytoreductive surgery in patients with ovarian carcinoma. Eur Radiol. 2013;23(9):2636-2642. https://doi.org/10.1007/s00330-013-2837-7
  47. Syrkashev EM, Solopova AE, Bychenko VG, Khabas GN. Modern imaging methods in the diagnosis and assessment of resectability of advanced ovarian cancer. Obstetrics and Gynecology. 2019;(10):66-74. (In Russ.). https://doi.org/10.18565/aig.2019.10.66-74
  48. Jamel S, Markar SR, Malietzis G, Acharya A, Athanasiou T, Hanna GB. Prognostic significance of peritoneal lavage cytology in staging gastric cancer: systematic review and meta-analysis. Gastric Cancer. 2018;21(1):10-18.  https://doi.org/10.1007/s10120-017-0749-y
  49. Ikoma N, Blum M, Chiang YJ, Estrella JS, Roy-Chowdhuri S, Fournier K, Mansfield P, Ajani JA, Badgwell BD. Yield of staging laparoscopy and lavage cytology for radiologically occult peritoneal carcinomatosis of gastric cancer. Ann Surg Oncol. 2016;23(13):4332-4337.
  50. De Andrade JP, Mezhir JJ. The critical role of peritoneal cytology in the staging of gastric cancer: an evidence-based review. J Surg Oncol. 2014;110(3):291-297.  https://doi.org/10.1002/jso.23632
  51. Mezhir JJ, Shah MA, Jacks LM, Brennan MF, Coit DG, Strong VE. Positive peritoneal cytology in patients with gastric cancer: natural history and outcome of 291 patients. Ann Surg Oncol. 2010;17(12):3173-3180. https://doi.org/10.1245/s10434-010-1183-0
  52. Liu S, He J, Liu S, Ji C, Guan W, Chen L, Guan Y, Yang X, Zhou Z. Radiomics analysis using contrast-enhanced CT for preoperative prediction of occult peritoneal metastasis in advanced gastric cancer. Eur Radiol. 2020;30(1):239-246.  https://doi.org/10.1007/s00330-019-06368-5
  53. Liu S, Shi H, Ji C, Zheng H, Pan X, Guan W, Chen L, Sun Y, Tang L, Guan Y, et al. Preoperative CT texture analysis of gastric cancer: correlations with postoperative TNM staging. Clin Radiol. 2018;73(8):756.e1-756.e9. 
  54. Jiang Y, Liang X, Wang W, et al. Noninvasive prediction of occult peritoneal metastasis in gastric cancer using deep learning. JAMA Netw Open. 2021;4(1):e2032269.
  55. Kim HY, Kim YH, Yun G, Chang W, Lee YJ, Kim B. Could texture features from preoperative CT image be used for predicting occult peritoneal carcinomatosis in patients with advanced gastric cancer? PLoS One. 2018;13(3):e0194755. https://doi.org/10.1371/journal.pone.0194755
  56. Scialpi M, Moschini TO, De Filippis G. PET/contrast-enhanced CT in oncology: «to do, or not to do, that is the question». Radiol Med. 2022;127(9):925-927.  https://doi.org/10.1007/s11547-022-01496-3
  57. Darweesh AA, Barakat AF, Dawoud MF, Shaban EA. Diagnostic value of positron emission tomography/computed tomography (PET/CT) in detection of peritoneal carcinomatosis. Egypt J Radiol Nucl Med. 2023;54(13):1-11.  https://doi.org/10.1186/s43055-023-00965-75
  58. Turlakow A, Yeung HW, Salmon AS, Macapinlac HA, Larson SM. Peritoneal carcinomatosis: role of (18) F-FDG PET. J Nucl Med. 2003;44(9):1407-1412. https://doi.org/10.1097/rlu.0000000000002650
  59. Lin EC. «Straight line» sign of diffuse peritoneal carcinomatosis on sagittal FDG positron emission tomographic images. Clin Nucl Med. 2002;27(10):735-736.  https://doi.org/10.1097/00003072-200210000-00014
  60. Wang X, Yang L, Wang Y. Meta-analysis of the diagnostic value of 18F-FDG PET/CT in the recurrence of epithelial ovarian cancer. Front Oncol. 2022;12:1003465. https://doi.org/10.3389/fonc.2022.1003465
  61. Expert Panel on Women’s Imaging; Kang SK, Reinhold C, Atri M, et al. ACR Appropriateness Criteria® Staging and follow-up of ovarian cancer. J Am Coll Radiol. 2018;15(5S):S198-S207.
  62. Fu L, Huang S, Wu H, Dong Y, Xie F, Wu R, Zhou K, Tang G, Zhou W. Superiority of [68 Ga]Ga-FAPI-04/[18 F]FAPI-42 PET/CT to [18 F]FDG PET/CT in delineating the primary tumor and peritoneal metastasis in initial gastric cancer. Eur Radiol. 2022;32:6281-6290.
  63. Zhao L, Pang Y, Luo Z, Fu K, Yang T, Sun L, Wu H, Lin Q, Chen H. Role of [68 Ga]Ga-DOTA-FAPI-04 PET/CT in the evaluation of peritoneal carcinomatosis and comparison with [18 F]-FDGPET/CT. Eur J Nucl Med Mol Imaging. 2021;48:1944-1955. https://doi.org/10.1007/s00259-020-05146-6
  64. Sollini M, Kirienko M, Gelardi F, Fiz F, Gozzi N, Chiti A. State-of-the-art of FAPI-PET imaging: a systematic review and meta-analysis. Eur J Nucl Med Mol Imaging. 2021;48(13):4396-4414. https://doi.org/10.1007/s00259-021-05475-0
  65. Zhao L, Chen J, Pang Y, Fu K, Shang Q, Wu H, Sun L, Lin Q, Chen H. Fibroblast activation protein-based theranostics in cancer research: a state-of-the-art review. Theranostics. 2022;12(4):1557-1569. https://doi.org/10.7150/thno.69475
  66. Fu L, Huang S, Wu H, Dong Y. Superiority of [68 Ga]Ga-FAPI-04/[18 F]FAPI-42 PET/CT to [18 F]FDG PET/CT in delineating the primary tumor and peritoneal metastasis in initial gastric cancer. Eur Radiol. 2022;32:1124-1131. https://doi.org/10.1007/s00330-022-08743-1
  67. Kratochwil C, Flechsig P, Lindner T, et al. 68 Ga-FAPI PET/CT: tracer uptake in28 different kinds of cancer. J Nucl Med. 2019;60(6):801-805. 
  68. Hu K, Wang L, Wu H, Huang S, Tian Y, Wang Q, Xiao C, Han Y, Tang G. [18 F]FAPI-42 PET imaging in cancer patients: optimal acquisition time, biodistribution, and comparison with [68 Ga]Ga-FA-PI-04. Eur J Nucl Med Mol Imaging. 2022;49:2833-2843. https://doi.org/10.1007/s00259-021-05646
  69. Gege Z, Xueju W, Bin J. Head-to-head comparison of 68Ga-FAPI PET/CT and FDG PET/CT for the detection of peritoneal metastases: systematic review and meta-analysis. AJR Am J Roentgenol. 2023;220(4):490-498.  https://doi.org/10.2214/ajr.22.28402
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.